Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2%
Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will
receive injections of ranibizumab. In addition, patients will receive either Squalamine
lactate 0.2% eye drops or Placebo eye drops. The study duration is approximately 9 months to
primary endpoint